Compare WIMI & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WIMI | NXL |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 7.5M |
| IPO Year | 2019 | 2022 |
| Metric | WIMI | NXL |
|---|---|---|
| Price | $0.61 | $2.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 156.4K | ★ 2.0M |
| Earning Date | 12-18-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $301,647.00 |
| Revenue This Year | $211.95 | $14.37 |
| Revenue Next Year | $7.11 | $100.00 |
| P/E Ratio | $1.24 | ★ N/A |
| Revenue Growth | N/A | ★ 78.78 |
| 52 Week Low | $0.44 | $0.22 |
| 52 Week High | $4.16 | $99.00 |
| Indicator | WIMI | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 32.27 | 31.26 |
| Support Level | N/A | $0.22 |
| Resistance Level | $1.43 | $5.36 |
| Average True Range (ATR) | 0.06 | 0.50 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 44.35 | 2.06 |
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.